References
- Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenkov Y, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:841–3.
- Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19:495–509.
- Foggetti G, Li C, Cai H, Hellyer JA, Lin WY, Ayeni D, Hastings K, Choi J, Wurtz A, Andrejka L, et al. Genetic determinants of EGFR-driven lung cancer growth and therapeutic response In vivo. Cancer Discov. 2021;11(7):1736–1753. doi:10.1158/2159-8290.CD-20-1385.
- Rogers ZN, McFarland CD, Winters IP, Naranjo S, Chuang CH, Petrov D, Winslow MM . A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. Nat Methods. 2017;14:737–742 doi:10.1038/nmeth.4297.
- Rogers ZN, McFarland CD, Winters IP, Seoane JA, Brady JJ, Yoon S, et al. Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice. Nat Genet. 2018;50:483–486 doi:10.1038/s41588-018-0083-2.
- Winters IP, Murray CW, Winslow MM. Towards quantitative and multiplexed in vivo functional cancer genomics. Nat Rev Genet. 2018;19(12):741–755. doi:10.1038/s41576-018-0053-7.
- van de Haar J, Canisius S, Yu MK, Voest EE, Wessels LFA, Ideker T. Identifying epistasis in cancer genomes: a delicate affair. Cell. 2019;177:1375–1383.
- Cai H, Chew SK, Li C, Tsai MK, Andrejka L, Murray CW, et al. A functional taxonomy of tumor suppression in oncogenic KRAS-driven lung cancer. Cancer Discov. 2021;11(7):1754–1773.
- Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-Mutated advanced NSCLC. N Engl J Med. 2020;382:41–50.
- Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-Mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711–1723.
- Li C, Lin WY, Rizvi H, Cai H, McFarland CD, Rogers ZN, et al. Quantitative in vivo analyses reveal a complex pharmacogenomic landscape in lung adenocarcinoma. Cancer Res. 2021;81(17):4570–4580.